Neuromuscular blockade in the intensive care unit

Seminars in Respiratory and Critical Care Medicine

Volumn 22, Issue 2, 2001, Pages 175-188

  Gehr, L C ^a   Sessler, C N ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Neuromuscular blocking agent; Peripheral nerve stimulation; Prolonged paralysis

Indexed keywords

ATRACURIUM; CISATRACURIUM; CURARE; DIMETHYLTUBOCURARINE CHLORIDE; DOXACURIUM; MIVACURIUM; NEUROMUSCULAR BLOCKING AGENT; PANCURONIUM; PIPECURONIUM; RAPACURONIUM BROMIDE; ROCURONIUM; VECURONIUM;

ARTIFICIAL VENTILATION; DRUG METABOLISM; INTENSIVE CARE UNIT; MYOPATHY; NERVE STIMULATION; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR SYNAPSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUADRIPLEGIA; REVIEW;

EID: 0034908094     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-13831     Document Type: Review

References (89)

1. Experiments and observations on different modes in which death is produced by certain vegetable poisons
2. Curari, the flying death
3. Use of sedating drugs and neuromuscular blocking agents in patients requiring mechanical ventilation for respiratory failure: A national survey
4. Use of sedatives, analgesics and neuromuscular blocking agents in Danish ICUs 1996/97: A national survey
5. Sedation of adult critically ill ventilated patients in intensive care units: A national survey
6. Patterns of prescribing and administering drugs for agitation and pain in patients in a surgical intensive care unit
7. Complications associated with sedative and neuromuscular blocking drugs in critically ill patients
8. Comparison of train-of-four and best clinical assessment during continuous paralysis
9. A prospective, randomized, controlled evaluation of peripheral nerve stimulation versus standard clinical dosing of neuromuscular blocking agents in critically ill patients
10. Pharmacoeconomic impact of rational use guidelines on the provision of analgesia, sedation, and neuromuscular blockade in critical care
11. Postal survey on the long-term use of neuromuscular block in the intensive care
12. Practice parameters for sustained neuromuscular blockade in the adult critically ill patient: An executive summary
13. Use of peripheral nerve stimulators to monitor patients with neuromuscular blockade in the ICU
14. A national survey on the practice patterns of anesthesiologist intensivists in the use of muscle relaxants
15. Are neuromuscular blocking agents more efficacious in Paris?
16. The nicotineic acetylcholine receptor: An allosteric protein prototype of ligand-gated ion channels
17. The nature of "depolarization block."
18. Antibiotics and neuromuscular function
19. Muscle relaxants
20. Pharmacokinetics and pharmacodynamics of steroid muscle relaxants
21. Nonrelaxant properties of neuromuscular blocking drugs
22. Modulation of histamine release by neuromuscular blocking drugs
23. Rocuronium anaphylaxis and multiple neuromuscular blocking drug sensitivities
24. Neuromuscular blocking agents in specific clinical situations
25. Pipecuronium and pancuronium: Comparison of pharmacokinetics and duration of action
26. Clinical pharmacokinetics of the newer neuromuscular blocking drugs
27. Pharmacokinetics and pharmacodynamics of doxacurium in normal patients and in those with hepatic or renal failure
28. Onset time, endotracheal intubating conditions, and plasma histamine after cisatracurium and vecuronium administration
29. The cerebral and cardiovascular effects of cisatracurium and atracurium in neurosurgical patients
30. Importance of the organ-independent elimination of cisatracurium
31. A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients
32. Comparison of the infusion requirements and recovery profiles of vecuronium and cisatracurium 51W89 in intensive care unit patients
33. Cisatracurium besilate: A review of its pharmacology and clinical potential in anaesthetic practice
34. The infusion requirements and recovery characteristics of cisatracurium or atracurium in intensive care patients
35. Neuromuscular blockade: Indications, peripheral nerve stimulation, and other concurrent interventions
36. On awakening paralyzed during surgery: A syndrome of traumatic neurosis
37. The experience of complete neuromuscular blockade in awake patients
38. Patient recall of therapeutic paralysis in a surgical critical care unit
39. Assessing sedation during intensive care unit mechanical ventilation with the Bispectral Index and the Sedation-Agitation Scale
40. Prolonged neuromuscular blockade after long-term administration of vecuronium in two critically ill patients
41. Clinical recovery and train-of-four ratio measured mechanically and electromyographically following atracurium
42. Vecuronium in patients with and without renal failure
43. Completely absent response to peripheral nerve stimulation in an acutely hypothyroid patient
44. Monitoring the administration of neuromuscular blockade in critical care
45. Real time versus slow-motion train-of-four monitoring: A theory to explain the inaccuracy of visual assessment
46. Differential effects of d-tubocurarine on inspiratory muscles and two peripheral muscle groups in anesthetized man
47. Monitoring of peripheral nerve stimulation versus standard clinical assessment for dosing of neuromuscular blocking agents
48. Relationship between post-tetanic count and response to carinal stimulation during vecuronium-induced neuromuscular blockade
49. Neuromuscular blocking drugs: Practical aspects of research in the intensive care unit
50. Comparison of twitch depression of the adductor pollicis and the respiratory muscles: Pharmacodynamic modeling without plasma concentrations
51. The impact of implementation of neuromuscular blockade monitoring standards in a surgical intensive care unit
52. Effects of hepatic uptake of vecuronium bromide and its putative metabolites on their neuromuscular blocking actions in the cat
53. Neuromuscular and vagal blocking actions of pancuronium bromide, its metabolites, and vecuronium bromide (Org NC45) and its potential metabolites in the anaesthetized cat
54. Doxacurium-corticosteroid acute myopathy: Another piece to the puzzle
55. Prolonged weakness after cisatracurium infusion: A case report
56. Persistent paralysis in critically ill patients after long-term administration of vecuronium
57. Acute myopathy associated with combined use of corticosteroids and neuromuscular blocking agents
58. Muscle weakness in mechanically ventilated patients with severe asthma
59. Neuromuscular disorder in intensive care unit patients treated with pancuronium bromide: Occurrence in a cluster group of seven patients and two sporadic cases, with electrophysiologic and histologic examination
60. Myopathy in severe asthma
61. Neuromuscular blockade in the intensive care unit: More than we bargained for
62. Critical illness polyneuropathy: A complication of sepsis and multiple organ failure
63. Critical illness polyneuropathy, facts and controversies
64. Disuse atrophy in a ventilated patient with status asthmaticus receiving neuromuscular blockade
65. Prolonged paralysis in intensive care unit patients after the use of neuromuscular blocking agents: A review of the literature
66. A comparison of cisatracurium (51W89) and atracurium by infusion in critically ill patients
67. Dose response, recovery, and cost of doxacurium as a continuous infusion in neurosurgical intensive care unit patients
68. Paralysis in the critically ill: Intermittent bolus pancuronium compared with continuous infusion
69. Severe myopathy after status asthmaticus
70. A syndrome of acute severe muscle necrosis in intensive care unit patients
71. Neuromuscular blocking agents in the intensive care unit: A two-edged sword
72. Neuromuscular complications in patients given Pavulon (pancuronium bromide) during artificial ventilation
73. Prolonged paralysis after treatment with neuromuscular junction blocking agents
74. Prolonged paralysis with atracurium infusion: A case report
75. Myopathy following mechanical ventilation for acute severe asthma: The role of muscle relaxants and corticosteroids
76. Acute quadriplegia and loss of muscle myosin in patients treated with nondepolarizing neuromuscular blocking agents and corticosteroids: Mechanisms at the cellular and molecular levels
77. Economic impact of prolonged motor weakness complicating neuromuscular blockade in the intensive care unit
78. Prolonged paralysis due to nondepolarizing neuromuscular blocking agents and corticosteroids
79. Prolonged weakness after infusion of atracurium in two intensive care unit patients
80. Critical care myopathy: An electrophysiological and histotogical study
81. Loss and renewal of thick myofilaments in glucocorticoid-treated rat soleus after denervation and reinnervation
82. A possible role for glucocorticoids in denervation atrophy
83. Acute myopathy associated with large parenteral dose of corticosteroid in myasthenia gravis
84. Neuromuscular conditions in the intensive care unit